Why Inovio Pharmaceuticals (INO) Stock Is Down Today

NEW YORK (TheStreet) -- Inovio Pharmaceuticals  (INO) fell Monday after the company reported first-quarter results that came up short of analysts' expectations.

Inovio reported a first-quarter loss of $10 million, or 5 cents a share, compared to a loss of $6.6 million, or 4 cents a share, in the same period one year earlier. This was slightly wider than the consensus estimate of a loss of 4 cents a share.

Revenue totaled $2.4 million, up year over year from $1.5 million. This surpassed analysts' estimates of $1.41 million; however, this increase was due primarily to $1.4 million attributable to the company's agreement with Roche. This portion of revenue mostly consisted of development fees paid for work Inovio performed in the first quarter.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 6.3% to $2.02 at 10:50 a.m.

INO Chart

INO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Dow Finishes Lower as Nasdaq Posts New Record

Dow Finishes Lower as Nasdaq Posts New Record

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations